Assessing Alphamab Oncology (SEHK:9966) Valuation After A Mixed Period Of Share Price Returns

Simply Wall St.

Apr 07

AdvertisementKey recent share performance Alphamab Oncology (SEHK:9966) has drawn attention after a mixed share performance, with a gain over the past week and month that contrasts with negative moves...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/2625193192"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2625193192\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2625193192?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-07 14:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625193192","market":"nz","top_or_hot":-1,"title":"Assessing Alphamab Oncology (SEHK:9966) Valuation After A Mixed Period Of Share Price Returns","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementKey recent share performance Alphamab Oncology (SEHK:9966) has drawn attention after a mixed share performance, with a gain over the past week and month that contrasts with negative moves...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/assessing-alphamab-oncology-sehk9966-valuation-after-a-mixed\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Alphamab Oncology (SEHK:9966) Valuation After A Mixed Period Of Share Price Returns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Alphamab Oncology (SEHK:9966) Valuation After A Mixed Period Of Share Price Returns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-07 14:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/assessing-alphamab-oncology-sehk9966-valuation-after-a-mixed><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementKey recent share performance Alphamab Oncology (SEHK:9966) has drawn attention after a mixed share performance, with a gain over the past week and month that contrasts with negative moves...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/assessing-alphamab-oncology-sehk9966-valuation-after-a-mixed\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/assessing-alphamab-oncology-sehk9966-valuation-after-a-mixed","article_id":"2625193192","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/assessing-alphamab-oncology-sehk9966-valuation-after-a-mixed","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625193192","pubTimestamp":1775542698,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Key recent share performance\nAlphamab Oncology (SEHK:9966) has drawn attention after a mixed share performance, with a gain over the past week and month that contrasts with negative moves over the past 3 months and year to date.\nSee our latest analysis for Alphamab Oncology.\nThe recent 7 day share price return of 15.9% and 30 day return of 15.16% off a HK$9.04 share price contrast with a weaker 90 day share price return of 11.37% and a mixed long term picture, with a 1 year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","09966":"康宁杰瑞制药-B","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK1574":"生物医药B类股"},"translate_title":"在股价回报喜忧参半后评估康宁杰瑞（联交所：9966）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09966":0.9,"DCF":1},"content_text":"AdvertisementKey recent share performance Alphamab Oncology (SEHK:9966) has drawn attention after a mixed share performance, with a gain over the past week and month that contrasts with negative moves over the past 3 months and year to date. See our latest analysis for Alphamab Oncology. The recent 7 day share price return of 15.9% and 30 day return of 15.16% off a HK$9.04 share price contrast with a weaker 90 day share price return of 11.37% and a mixed long term picture, with a 1 year total shareholder return of 49.67% against a 3 year total shareholder loss of 43.85%. If this kind of rebound has you thinking about what else could be setting up for a shift in sentiment, it may be worth scanning 128 healthcare AI stocks So with Alphamab Oncology trading close to its HK$9.61 price target, while still posting losses and a low value score of 2, are you looking at an undervalued oncology specialist or a market that has already priced in its prospects? Preferred Price-to-Sales of 13.6x: Is it justified? On a P/S of 13.6x, Alphamab Oncology looks expensive versus its estimated fair P/S of 8.9x, even though it sits roughly in line with biotech peers. The P/S ratio compares the company’s HK$9.04 share price to its HK$566.24m of revenue. This is a common way to look at early stage or loss making biopharma names. For Alphamab Oncology, the current 13.6x P/S implies investors are willing to pay a high price today relative to the sales the business is generating. Against that, the market seems to be weighing strong revenue growth expectations, with forecasts pointing to 21.4% a year. That is faster than both the wider Hong Kong market at 8.4% a year and the 20% threshold often used to flag higher growth names. Even so, the fair P/S estimate of 8.9x suggests the current valuation sits a clear step above a level the market could move towards if sentiment or growth expectations cool. Compared with the Hong Kong Biotechs industry average P/S of 13.7x and a peer average of 14.7x, Alphamab Oncology screens as roughly in line or slightly cheaper than its closest comparables on this simple metric. However, when set against the lower fair P/S ratio of 8.9x, the stock still looks priced at a premium that the broader peer and fair value work do not fully support. Explore the SWS fair ratio for Alphamab Oncology Result: Price-to-sales of 13.6x (OVERVALUED) However, there are still clear risks here, including ongoing losses of CN¥113.94m and heavy reliance on a single market in the PRC, which accounts for HK$566.24m of revenue. Find out about the key risks to this Alphamab Oncology narrative. Another view from our DCF model The SWS DCF model points in the same direction as the P/S work, with Alphamab Oncology at HK$9.04 trading above an estimated cash flow value of HK$7.44. That gap suggests limited margin of safety at today’s price. The question is whether you think the market is being too cautious or not cautious enough. Look into how the SWS DCF model arrives at its fair value. 9966 Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Alphamab Oncology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 247 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With the picture so mixed, it helps to pressure test the numbers yourself and decide whether the current pricing matches your expectations. To see what the market is optimistic about, review the 1 key reward Looking for more investment ideas? Do not stop with a single stock when you can quickly spot other opportunities that fit your style, risk comfort, and income goals on one dashboard.  Target potential mispricings by scanning 247 high quality undervalued stocks and quickly see which names might offer more for every dollar paid. Strengthen your income stream by checking 489 dividend fortresses and focus on companies that pair higher yields with staying power. Sleep easier by reviewing 287 resilient stocks with low risk scores so you can focus on businesses where the risk score is already doing some of the heavy lifting.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}